Dendritic cell vaccine - Immunicum

Drug Profile

Dendritic cell vaccine - Immunicum

Alternative Names: Allogeneic cancer vaccine - Immunicum; COMBIG-DC; INTUVAX-GIST; INTUVAX-HCC; INTUVAX-RCC

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunicum
  • Developer Immunicum; Uppsala University
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal cell carcinoma
  • Phase I Gastrointestinal stromal tumours; Hepatocellular carcinoma

Most Recent Events

  • 28 Jun 2017 Immunicum completes a phase I trial in Hepatocellular carcinoma in Sweden (NCT01974661)
  • 01 Jun 2016 Phase-I clinical trials in Gastrointestinal stromal tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in Sweden (Intratumoural) (NCT02686944)
  • 24 Feb 2016 Immunicum plans a phase I trial for Gastrointestinal stromal tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Sweden (NCT02686944)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top